Shire plc (the “Company”) (LSE: SHP, NASDAQ: SHPG) is today publishing the audited consolidated financial statements for ViroPharma Incorporated, dated April 29, 2014, for the year ending December 31, 2013.
For further information please contact:
Jeff Poulton [email protected]
+1 781 482 0945
Sarah Elton-Farr [email protected]
+44 1256 894157
Stephanie Fagan[email protected]
+1 781 482 0460
Gwen Fisher[email protected]
+1 484 595 9836
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
Click here for the PDF version of this press release.